Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weller, T. M. A.
Right arrow Articles by Wise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weller, T. M. A.
Right arrow Articles by Wise, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 177-184
© 2002 The British Society for Antimicrobial Chemotherapy

Brief report

The in vitro activity of BMS-284756, a new des-fluorinated quinolone

T. M. A. Weller,*, J. M. Andrews, G. Jevons and R. Wise

Department of Medical Microbiology, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK

The in vitro activity of BMS-284756 (previously T-3811ME), a des-fluoro(6) quinolone, was investigated and compared with those of six other antimicrobial agents. Susceptibility tests were performed on 919 Gram-positive, Gram-negative (including nine quinolone-resistant Escherichia coli) and anaerobic bacteria, three Chlamydia isolates and four Mycobacteria spp. BMS-284756 was marginally less active against the Enterobacteriaceae, but was the most active quinolone against staphylococci, enterococci and peptostreptococci. Against Streptococcus pneumoniae, BMS-284756 and gemifloxacin were more active than other quinolones. The MIC90 of BMS-284756 was >= 2 mg/L for the following bacteria: E. coli (MIC90 16 mg/L), Acinetobacter spp. (8 mg/L), Pseudomonas aeruginosa (64 mg/L) and Enterococcus faecium (4 mg/L). The MIC of BMS-284756 for Mycobacterium spp. was within one dilution of the MIC of ciprofloxacin. BMS-284756 was markedly more active than ciprofloxacin against the Chlamydia isolates tested.

* Corresponding author. Tel: +44-121-507 5742; Fax: +44-121-551-7763; E-mail: T.M.A.Weller{at}bham.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
G. Krishna, J. C. Kisicki, S. Olsen, D. M. Grasela, and Z. Wang
The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers
J. Clin. Pharmacol., May 1, 2007; 47(5): 628 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Tanaka, H. Mikamo, K. Nakao, and K. Watanabe
In Vitro Antianaerobic Activity of DX-619, a New Des-Fluoro(6) Quinolone
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3908 - 3913.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Fukuda, K. Yanagihara, H. Ohno, Y. Higashiyama, Y. Miyazaki, K. Tsukamoto, Y. Hirakata, K. Tomono, Y. Mizuta, T. Tashiro, et al.
In Vivo Efficacies and Pharmacokinetics of DX-619, a Novel Des-Fluoro(6) Quinolone, against Streptococcus pneumoniae in a Mouse Lung Infection Model
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 121 - 125.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. E. Edmiston Jr, C. J. Krepel, K. S. Kehl, G. R. Seabrook, L. B. Somberg, G. H. Almassi, T. L. Smith, T. A. Loehrl, K. R. Brown, B. D. Lewis, et al.
Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients
J. Antimicrob. Chemother., November 1, 2005; 56(5): 872 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. J. Christiansen, J. M. Bell, J. D. Turnidge, and R. N. Jones
Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. P. Smith, A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp
In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2081 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Vera-Cabrera, E. Y. Ochoa-Felix, G. Gonzalez, R. Tijerina, S. H. Choi, and O. Welsh
In Vitro Activities of New Quinolones and Oxazolidinones against Actinomadura madurae
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1037 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Vera-Cabrera, E. Gonzalez, S. H. Choi, and O. Welsh
In Vitro Activities of New Antimicrobials against Nocardia brasiliensis
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 602 - 604.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. N. Jones, K. A. Gordon, and D. J. Biedenbach
Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study
J. Antimicrob. Chemother., February 1, 2004; 53(2): 258 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Andes and W. A. Craig
Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3935 - 3941.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Liebetrau, A. C. Rodloff, J. Behra-Miellet, and L. Dubreuil
In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria
Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3667 - 3671.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M.-I. Morosini, E. Loza, R. del Campo, F. Almaraz, F. Baquero, and R. Canton
Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases
Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2692 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. W. Hecht and J. R. Osmolski
Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 910 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
X. Zhao, W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica
Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1023 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Andrews, D. Honeybourne, G. Jevons, M. Boyce, R. Wise, A. Bello, and D. Gajjar
Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects
J. Antimicrob. Chemother., March 1, 2003; 51(3): 727 - 730.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.